Lucentis treatment may help people with type 1 diabetes or type 2 diabetes improve vision

Many patients who have type 1 diabetes or type 2 diabetes are warned that poor diabetes management can result in serious health complications, including blindness.

Loss of vision can significantly decrease an individual's quality of life, sometimes rendering them incapable of engaging in their normal daily activities.

However, a recent article published by Bloomberg reported that a drug manufactured by Roche Holding AG, called Lucentis, may help people with type 1 diabetes or type 2 diabetes regain their vision.

The news provider cited findings from a study that was presented at a meeting of the American Diabetes Association held in San Diego, California.

The research involved more than 750 patients with diabetic macular edema, which is characterized by the excessive growth of blood vessels in the eye, which can cause some vessels to leak and damage an individual's retina.

The news source explained that the condition is the leading cause of blindness among working-age U.S. adults.

According to results from one part of the clinical trial, 15 percent and 34 percent of participants who received low and high doses of Lucentis, respectively, were able to read 15 more letters on an eye exam than they could prior to treatment.

“We now have a treatment that causes a rapid, significant and sustained improvement. Getting 60 percent of patients to 20/40 vision, allowing them to drive without restrictions is significant," said researcher David Boyer, quoted by the news source.

The American Diabetes Association recommends that individuals with type 1 diabetes or type 2 diabetes should have a dilated eye exam at least once every year, even if their eye health seems to be in good order.

Diabetics who experience problems with their vision such as floating dark spots, flashing lights or complete blackness in one or both eyes should seek medical attention as soon as possible, the organization notes.